2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, May 29 at 4:57 p.m. CDT (Abstract #5508), the oral presentation titled, “A phase 1/2 study of the next-generation Nectin-4-targeting antibody drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic cervical cancer,” will be presented by Professor Yohann Loriot, Gustave Roussy (Paris).
Saturday, May 30 at 4:30 p.m. CDT (Abstract #6062/Poster #519), the poster presentation titled, “A phase 1/2 study of the next-generation Nectin-4-targeting antibody drug conjugate CRB-701 (SYS6002) in patients with recurrent or metastatic head and neck squamous cell carcinoma,” will be presented by Charlene Mantia, M.D., Dana-Farber Cancer Institute (Boston).